- Home
- OP vs SBFM Comparison
OP vs SBFM Comparison
Compare OP & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- SBFM
- Stock Information
- Founded
- OP 2021
- SBFM 2006
- Country
- OP Greece
- SBFM United States
- Employees
- OP N/A
- SBFM N/A
- Industry
- OP
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- SBFM Health Care
- Exchange
- OP Nasdaq
- SBFM Nasdaq
- Market Cap
- OP 8.3M
- SBFM 6.3M
- IPO Year
- OP N/A
- SBFM N/A
- Fundamental
- Price
- OP $0.90
- SBFM $1.91
- Analyst Decision
- OP
- SBFM Strong Buy
- Analyst Count
- OP 0
- SBFM 1
- Target Price
- OP N/A
- SBFM $15.00
- AVG Volume (30 Days)
- OP 12.0K
- SBFM 48.0K
- Earning Date
- OP 04-10-2025
- SBFM 03-27-2025
- Dividend Yield
- OP N/A
- SBFM N/A
- EPS Growth
- OP N/A
- SBFM N/A
- EPS
- OP N/A
- SBFM N/A
- Revenue
- OP $25,729,000.00
- SBFM $32,959,491.00
- Revenue This Year
- OP N/A
- SBFM $59.94
- Revenue Next Year
- OP N/A
- SBFM $164.69
- P/E Ratio
- OP N/A
- SBFM N/A
- Revenue Growth
- OP 36.33
- SBFM 61.94
- 52 Week Low
- OP $0.88
- SBFM $1.90
- 52 Week High
- OP $3.15
- SBFM $266.00
- Technical
- Relative Strength Index (RSI)
- OP 29.68
- SBFM 28.63
- Support Level
- OP $0.88
- SBFM $2.02
- Resistance Level
- OP $0.99
- SBFM $2.49
- Average True Range (ATR)
- OP 0.06
- SBFM 0.18
- MACD
- OP -0.01
- SBFM -0.02
- Stochastic Oscillator
- OP 6.54
- SBFM 1.70
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.